C
Chunhong Hu
Researcher at Central South University
Publications - 81
Citations - 5376
Chunhong Hu is an academic researcher from Central South University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 13, co-authored 56 publications receiving 4201 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi,Li Zhang,Xiaoqing Liu,Caicun Zhou,Shucai Zhang,Dong Wang,Qiang Li,Shukui Qin,Chunhong Hu,Yiping Zhang,Jianhua Chen,Ying Cheng,Jifeng Feng,Helong Zhang,Yong Song,Yi-Long Wu,Nong Xu,Jianying Zhou,Rongcheng Luo,Chunxue Bai,Ye-ning Jin,Wenchao Liu,Zhaohui Wei,Fenlai Tan,Yinxiang Wang,Lieming Ding,Hong Dai,Shunchang Jiao,Jie Wang,Li Liang,Weimin Zhang,Yan Sun +31 more
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Xiaoqing Liu,Yunzhong Zhu,Shun Lu,Jifeng Feng,Jianxing He,Baohui Han,Jie Wang,Guo-Liang Jiang,Chunhong Hu,Hao Zhang,Gang Cheng,Xiangqun Song,You Lu,Hongming Pan,Wenjuan Zheng,Anny-Yue Yin +18 more
TL;DR: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC.
Journal ArticleDOI
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Jie Wang,Shun Lu,Xinmin Yu,Yanping Hu,Yuping Sun,Zhijie Wang,Jun Zhao,Yan Yu,Chunhong Hu,Kunyu Yang,Guosheng Feng,Kejing Ying,Wu Zhuang,Jianying Zhou,Jingxun Wu,Shiang Jiin Leaw,Jing Zhang,Xiao Lin,Liang Liang,Nong Yang +19 more
TL;DR: In this paper, tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC).
Journal ArticleDOI
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Hai Qiang Mai,Qiu Yan Chen,Dongping Chen,Chaosu Hu,Kun-Yu Yang,Jiyu Wen,Jingao Li,Ying Rui Shi,Feng Jin,Ruilian Xu,Jianji Pan,Shenhong Qu,Ping Li,Chunhong Hu,Yi-Chun Liu,Yi Jiang,Xia He,Hung-Ming Wang,Wan-Teck Lim,Wangjun Liao,Xiaohui He,Xiaozhong Chen,Zhigang Liu,Xianglin Yuan,Qi Li,Xiaoyan Lin,Shanghua Jing,Yanju Chen,Yin Lu,Ching Yun Hsieh,Muh Hwa Yang,Chia Jui Yen,Jens Samol,Jens Samol,Hui Feng,Sheng Yao,Patricia Keegan,Rui-Hua Xu +37 more
TL;DR: In this article, toripalimab was added to standard gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma.